Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO
Imaging Technology
OCTOBER 5, 2023
Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We
Let's personalize your content